8WK Stock Overview
A platform and vaccine development company, research, design, and develops vaccines and immunotherapies based on its proprietary vaccine delivery platform in Sweden and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Abera Bioscience AB Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.33 |
| 52 Week High | SEK 0.51 |
| 52 Week Low | SEK 0.28 |
| Beta | 1.04 |
| 11 Month Change | 3.13% |
| 3 Month Change | -3.52% |
| 1 Year Change | -16.50% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -71.34% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8WK | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 1.5% | 0.8% | -1.3% |
| 1Y | -16.5% | -17.5% | 7.4% |
Return vs Industry: 8WK exceeded the German Biotechs industry which returned -17.5% over the past year.
Return vs Market: 8WK underperformed the German Market which returned 7.4% over the past year.
Price Volatility
| 8WK volatility | |
|---|---|
| 8WK Average Weekly Movement | 6.1% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 8WK has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 8WK's weekly volatility has decreased from 13% to 6% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 6 | Maria Alriksson | aberabio.com |
Abera Bioscience AB, a platform and vaccine development company, research, design, and develops vaccines and immunotherapies based on its proprietary vaccine delivery platform in Sweden and internationally. The company’s development platform named BERA, uses for the display of antigens at the surface of outer membrane vesicles derived from genetically optimized gram-negative bacteria. Its lead vaccine candidate is a universal pneumococcal vaccine based on the platform BERA.
Abera Bioscience AB Fundamentals Summary
| 8WK fundamental statistics | |
|---|---|
| Market cap | €5.55m |
| Earnings (TTM) | -€323.31k |
| Revenue (TTM) | €1.10m |
5.1x
P/S Ratio-17.2x
P/E RatioIs 8WK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8WK income statement (TTM) | |
|---|---|
| Revenue | SEK 12.60m |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 12.60m |
| Other Expenses | SEK 16.32m |
| Earnings | -SEK 3.72m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.26 |
| Gross Margin | 100.00% |
| Net Profit Margin | -29.50% |
| Debt/Equity Ratio | 0% |
How did 8WK perform over the long term?
See historical performance and comparison